DIASORIN: PUBLICATION OF THE SUMMARY REPORT OF THE VOTES CAST

Saluggia, May 2, 2022 – DiaSorin S.p.A. (FTSE MIB: DIA) (the “Company”) hereby gives notice that, pursuant to applicable laws and regulations, the summary report of the votes cast at the ordinary meeting of shareholders of the Company, held on April 29, 2022, was made available to the public today on the Company’s corporate website (www.diasoringroup.com, section “Governance”, “Shareholders Meeting”, “2022”).

For additional information, please contact:

Riccardo Fava
Corporate Vice President Communication & Investor Relations
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Emanuela Salvini
Investor Relator
Tel: +39.0161.487567
emanuela.salvini@diasorin.it

About DiaSorin
Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide. The Group operates in 5 continents through 43 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”. More info at www.diasoringroup.com